Drawing for SOLYMBIC

USPTO serial 86971830

SOLYMBIC

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
GOODWIN, KATRINA JOYE
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SOLYMBIC?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Timothy J. Gaul

Timothy J. Gaul Amgen Inc.One Amgen Center DriveTrademark Operations-MS-28-5AThousand Oaks, CA 91320-1799

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations and substances used for the treatment of bone, joint, intestine, colon, skin, lung, eye, bladder, blood cells, and blood vessel diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune and immune system, inflammatory, inflammatory bowel, gastrointestinal, musculoskeletal, dermatological, pulmonary, respiratory, oncological, and ophthalmic diseases and disorders; pharmaceutical preparations and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, acute disc prolapse, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Intestinal Behçet's Disease, chronic pouchitis, small bowel lesions, Hermansky-Pudlak syndrome, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, hidradenitis suppurativa, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, uveitis, choroidal neovascularization, Pyoderma Gangrenosum, giant cell arteritis, Netherton syndrome, anaplastic thyroid cancers, asthma, and refractory asthmaACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jul 13, 2020MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 13, 2020ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 19, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 18, 2019EX5GSOU EXTENSION 5 GRANTED—
Nov 18, 2019AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Nov 13, 2019EXT5SOU EXTENSION 5 FILED—
Nov 13, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 28, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 24, 2019EX4GSOU EXTENSION 4 GRANTED—
May 24, 2019EXT4SOU EXTENSION 4 FILED—
May 24, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 7, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 7, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Nov 23, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 21, 2018EX3GSOU EXTENSION 3 GRANTED—
Nov 21, 2018EXT3SOU EXTENSION 3 FILED—
Nov 21, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 26, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 24, 2018EX2GSOU EXTENSION 2 GRANTED—
May 24, 2018EXT2SOU EXTENSION 2 FILED—
May 24, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 17, 2017EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 15, 2017EX1GSOU EXTENSION 1 GRANTED—
Nov 15, 2017EXT1SOU EXTENSION 1 FILED—
Nov 15, 2017EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 6, 2017NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 11, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 11, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 22, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 3, 2017PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 13, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 10, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 10, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 7, 2017ALIEASSIGNED TO LIE—
Jan 23, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 29, 2016GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jul 29, 2016GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jul 29, 2016CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jul 26, 2016DOCKASSIGNED TO EXAMINER—
Jul 25, 2016DOCKASSIGNED TO EXAMINER—
Apr 15, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 14, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance